€29.00 PSG.DE PharmaSGP SE (XETRA) intraday 10 Feb 2026: oversold bounce

PSG.DE stock trades at €29.00 intraday on XETRA on 10 Feb 2026 as volume ticks higher, setting up an oversold bounce opportunity. The stock opened at €28.80, hit a day low of €28.60, and has a relative volume of 2.30, suggesting active short-term interest. We examine technical triggers, valuation, and a trading plan for an intraday bounce in Germany’s healthcare segment.

Intraday price action and technical setup for PSG.DE stock

PSG.DE stock is showing a tight intraday range with a day high €29.00 and day low €28.60. Volume is 12,424.00 versus an average of 5,399.00, which supports a higher-probability bounce trade. The 50-day average €28.52 sits just below the current price, providing a near-term support band. Keltner channels (lower €28.20, middle €29.00, upper €29.80) show the stock trading around the middle channel, useful for an oversold bounce entry.

Valuation and fundamentals: quick metrics

At €29.00 PSG.DE reports EPS €1.68 and a quoted PE of 17.26 on the quote feed, while Meyka metrics show a TTM PE of 21.46, reflecting timing differences. Market cap is €333,862,500.00 and shares outstanding are 11,512,500.00. Key ratios include current ratio 2.68, debt to equity 0.02, and free cash flow yield 0.07. High gross margin 90.49% and net margin 16.59% support profitability, though inventory days are long at 400.36.

Catalysts, calendar and headline risk for PSG.DE stock

No scheduled earnings until 2025-09-11 per the quote feed, so intraday moves are supply-demand driven. Export exposure across EU markets and product portfolio in OTC pain and wellness products means consumer confidence and pharmacy ordering cycles can move sales. Watch for regulatory bulletins, pharmacy chain purchasing updates, or distribution agreements that could shift intraday sentiment.

Meyka AI grade and price forecast for PSG.DE

Meyka AI rates PSG.DE with a score out of 100: 79.10 (Grade B+, Suggestion: BUY). This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects €27.36 for one year, €29.48 in three years, and €31.56 in five years. These model projections are not guarantees and should be used alongside risk management.

Oversold bounce trade plan and risk management

For an intraday oversold bounce on PSG.DE stock consider a layered entry between €28.65 and €28.90 with a tight stop below €28.40 to limit downside. Target zones for partial exits: €29.60 (near short-term resistance) and €30.00 (year high). Use position sizing so a stop loss equals no more than 1.0% to 2.0% of portfolio risk on the trade. If volume fades, respect the stop and avoid averaging down.

Sector context, liquidity and broader market signals

PharmaSGP sits in the Healthcare sector on XETRA where average PE is higher; sector performance YTD is modest. PSG.DE’s 50-day average volume 5,399.00 makes it a thinly traded small-cap, so intraday spikes in volume can exaggerate moves. Compare sector peers for relative strength and watch broader market risk-on flows in Germany for confirmation before committing capital.

Final Thoughts

Intraday, PSG.DE stock at €29.00 looks set for a tactical oversold bounce backed by above-average volume 12,424.00 and proximity to the 50-day moving average €28.52. Meyka AI’s forecast model projects €27.36 in one year (implied downside -5.72% vs current price), €29.48 in three years (implied upside +1.66%), and €31.56 in five years (implied upside +8.83%). Our bias for today is tactical and short-term: a measured long on a clear bounce signal with a stop around €28.40 and targets at €29.60 and €30.00. Remember that forecasts are model‑based projections and not guarantees. Use strict risk controls given PSG.DE’s thin trading depth, and consult the company website for corporate news PharmaSGP website and XETRA liquidity notices Deutsche Börse. For an updated quote and live tools visit our Meyka page for PSG.DE Meyka PSG.DE page.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.